Artemisinin and derivatives: The future for malaria treatment?

Current Opinion in Infectious Diseases

Volumn 14, Issue 6, 2001, Pages 719-726

  Haynes, R K ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEETHER; ARTEMETHER; ARTEMISININ; ARTESUNATE;

ANTIMALARIAL ACTIVITY; DERIVATIZATION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STABILITY; HUMAN; MALARIA; NEUROTOXICITY; REVIEW;

EID: 0035208051     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200112000-00010     Document Type: Review

References (68)

1. A new drug for malaria
2. The use of artemisinin and its derivatives as anti-malarial drugs
3. Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria
4. Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria
5. Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria
6. Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria
7. Chemical stability of artesunate injection and proposal for its administration by intravenous infusion
8. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin
9. Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19
10. Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's
11. The catalytic pathway of cytochrome P450cam at atomic resolution
12. Clinical pharmacokinetics of artemether and lumefantrine (Riamet)
13. Current progress in the chemistry, medicinal chemistry and drug design of artemisinin-based antimalarials
14. Hepatic metabolism of artemisinin drugs - I. Drug metabolism in rat liver microsomes
15. Hepatic metabolism of artemisinin drugs - II. Metabolism of arteether in rat liver cytosol
16. New insights into the degradation of qinghaosu (artemisinin) mediated by non-haem-iron chelates, and their relevance to antimalarial mechanism
17. Inactivation of artemisinin by thalassemic erythrocytes
18. Animal pharmacokinetics and metabolism of the new antimalarial Ro 42-1611 (arteflene)
19. Biliary metabolites of beta-artemether in rats: Biotransformations of an antimalarial endoperoxide
20. Declining concentrations of dihydroartemisinin in plasma during 5-day oral treatment with artesunate for falciparum malaria
21. High in situ rat intestinal permeability of artemisinin unaffected by multiple dosing and with no evidence of P-glycoprotein involvement
22. Pharmacokinetic interaction trial between co-artemether and mefloquine
23. Artemisinin and the antimalarial endoperoxides: From herbal remedy to targeted chemotherapy
24. Possible modes of action of the artemisinin·type compounds
25. Characterization of the alkylation product of heme by the antimalarial drug artemisinin
26. Effects of dihydroartemisinin on fine structure of erythrocytic stages of Plasmodium berghei ANKA strain
27. Artemisinin and its derivatives are transported by a vacuolar-network of Plasmodium falciparum and their anti-malarial activities are additive with toxic sphingolipid analogues that block the network
28. Changing ideas on chloroquine in Plasmodium falciparum
29. Declining concentrations of dihydroartemisinin in plasma during 5-day oral treatment with artesunate for falciparum malaria
30. Antimalarial drug resistance and combination chemotherapy
31. Plasmodium falciparum antimalarial drug susceptibility on the North-Western border of Thailand during five years of extensive use of artesunate-mefloquine
32. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: A prospective study
33. Dose-finding study of the efficacy of fixed·combination artemether/lumefantrine for the treatment of multidrug-resistant Plasmodium talciparum malaria in Thailand
34. Pharmacokinetic interaction trial between co-artemether and mefloquine
35. Artemether-lumifantrine for the treatment of multidrug-resistant falciparum malaria
36. Pharmacokinetics and pharmacodynamics of lumefantrine (Benflumetol) in acute falciparum malaria
37. Clinical pharmacokinetics of artemether and lumefantrine (Riamet)
38. Efficacy of artesunate plus pyrimethamine-sulfadoxine for uncomplicated malaria in Gambian children: A double-blind, randomized, controlled trial
39. Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand
40. The chemotherapy of rodent malaria. Part 58. Drug combinations to impede the selection of drug resistance, Part 2. The new generation - Artemisinin or artesunate with long-acting blood schizontocides
41. Combinations of artemisinin and quinine for uncomplicated falciparum malaria: Efficacy and pharmacodynamics
42. Behavioral and neural toxicity of the artemisinin antimalarial arteether, but not artesunate and artelinate, in rats
43. Establishment of an in vitro screening model for neurodegeneration induced by antimalarial drugs of the artemisinin·type
44. The role of glutathione in the neurotoxicity of artemisinin derivatives in vitro
45. The behaviour of qinghaosu (artemisinin) in the presence of heme iron(II) and (III)
46. Extraction of qinghaosu (artemisinin) and qinghao (artemisinic) acid: Preparation of artemether and new analogues
47. Antimalarial sulfide, sulfone, and sulfonamide trioxanes
48. Synthesis and in vitro antimalarial activity of sulfone endoperoxides
49. Synthesis and antimalarial activities of base-catalyzed adducts of 11-azaartemisinin
50. Synthesis and antimalarial activity of artemisinin derivatives containing an amino group
51. C-10-fluorinated derivatives of dihydroartemisinin: Difluoromethylene ketones
52. Antimalarial artemisinin analogs. Synthesis via chemoselective C-C bond formation and preliminary biological evaluation
53. Efficient preparation of novel qinghaosu (artemisinin) derivatives: Conversion of qinghao (artemisinic) acid into deoxoqinghaosu derivatives and 5-carba-4-deoxoartesunic acid
54. Orally active, hydrolytically stable, semisynthetic, antimalarial trioxanes in the artemisinin family
55. Acid catalyzed Michael additions to artemisitene
56. Synthesis, antimalarial activity, biomimetic iron(II) chemistry, and in vivo metabolism of novel, potent C-10-phenoxy derivatives of dihydroartemisinin
57. Experimental and computational approaches to estimate solubility in drug discovery and development settings
58. Quantitative structure-activity relationships (QSAR)
59. Synthesis, characterization and antimalarial activity of the glucuronides of the hydroxylated metabolites of arteether
60. Structure-activity relationships of the antimalarial agent artemisinin. 5. Analogs of 10-deoxoartemisinin substituted at C-3 and C-9
61. CNS drug design based on principles of blood-brain barrier transport
62. Bioisosteres, conformational restriction and pro-drugs - Case history: An example of a conformational restriction approach
63. The behaviour of qinghaosu (artemisinin) in the presence of non-heme iron(II) and (III)